<DOC>
	<DOCNO>NCT02222090</DOCNO>
	<brief_summary>The aim present registry characterize follow patient prospectively retrospectively renal impairment prescribe apixaban prevention stroke atrial fibrillation , comparison characteristic outcomes associate warfarin therapy population .</brief_summary>
	<brief_title>Therapy With New Oral Anticoagulants</brief_title>
	<detailed_description>Current guideline management patient atrial fibrillation ( AF ) recommend use novel oral anticoagulant ( NOACs ) patient non-valvular AF .Renal dysfunction show independent predictor stroke systemic embolus , risk bleed conventional warfarin therapy also significantly increased.Prevalence renal dysfunction patient atrial fibrillation high , approximately 60 % patient estimate glomerular filtration rate ( eGFR ) â‰¤ 60 ml/min/BSA [ 6 ] .NOACs undergo significant renal secretion dabigatran recommend patient severe renal impairment , dose adjustment indicate patient milder degree renal dysfunction.However , real-world information regard usage outcomes associate NOAC therapy patient renal dysfunction limit . The investigator plan prospectively retrospectively collect data regard clinical setting , characteristic , outcomes patient renal dysfunction prescribe apixaban Israel , use multicenter secure web-based registry .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Patients renal dysfunction ( eGFR &lt; 60 ml\min\BSA ) indication treatment novel oral anticoagulant agent VKA Patients prescribed apixaban warfarin enrollment center ( patient enrol 2:1 ratio ) Valvular AF presence prosthetic valve Dialysis patient Contraindications NOACs Hepatic dysfunction Cognitive impairment Clinical necessity continue administration potent inhibitor CYP3A4 Pgp include azole antimycotic ( e.g . ketoconazole , itraconazole ) HIV protease inhibitor ( e.g . ritonavir )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>patient atrial fibrillation ( AF ) recommend use novel oral anticoagulant ( NOACs ) patient non-valvular AF</keyword>
</DOC>